Last reviewed · How we verify

Medical Standard of Care for ITP

Amgen · Phase 3 active Small molecule

Medical Standard of Care for ITP is a Small molecule drug developed by Amgen. It is currently in Phase 3 development for Immune thrombocytopenia (ITP).

This represents the established standard treatment approach for immune thrombocytopenia (ITP), which typically aims to increase platelet counts through immune modulation or platelet production stimulation.

This represents the established standard treatment approach for immune thrombocytopenia (ITP), which typically aims to increase platelet counts through immune modulation or platelet production stimulation. Used for Immune thrombocytopenia (ITP).

At a glance

Generic nameMedical Standard of Care for ITP
SponsorAmgen
ModalitySmall molecule
Therapeutic areaImmunology / Hematology
PhasePhase 3

Mechanism of action

Medical standard of care for ITP generally includes corticosteroids as first-line therapy to suppress the immune system's attack on platelets, often combined with intravenous immunoglobulin (IVIG) or anti-D immunoglobulin in acute cases. For chronic ITP, thrombopoietin receptor agonists (TPO-RAs) are commonly used to stimulate megakaryocyte development and platelet production. The specific mechanism depends on which standard-of-care agent is being evaluated in the phase 3 trial.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Medical Standard of Care for ITP

What is Medical Standard of Care for ITP?

Medical Standard of Care for ITP is a Small molecule drug developed by Amgen, indicated for Immune thrombocytopenia (ITP).

How does Medical Standard of Care for ITP work?

This represents the established standard treatment approach for immune thrombocytopenia (ITP), which typically aims to increase platelet counts through immune modulation or platelet production stimulation.

What is Medical Standard of Care for ITP used for?

Medical Standard of Care for ITP is indicated for Immune thrombocytopenia (ITP).

Who makes Medical Standard of Care for ITP?

Medical Standard of Care for ITP is developed by Amgen (see full Amgen pipeline at /company/amgen).

What development phase is Medical Standard of Care for ITP in?

Medical Standard of Care for ITP is in Phase 3.

What are the side effects of Medical Standard of Care for ITP?

Common side effects of Medical Standard of Care for ITP include Infection, Bleeding, Thrombosis (with TPO-RAs), Hyperglycemia (with corticosteroids).

Related